Abbreviations: aaIPI = Age-adjusted International Prognostic Index; DLBCL = diffuse large-B-cell lymphoma; LVEF = left ventricular ejection fraction; MCL = mantle-cell lymphoma; R-DHAP = rituximab-dexamethasone aracytine carboplatine; TCLO = transfert lung factor for CO. 
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). 1, 2 Although the role of ASCT as part of first line treatment remains controversial for patients with diffuse large-B-cell lymphoma (DLBCL), high-dose chemotherapy followed by ASCT has been shown to be superior to standard chemotherapy in poor-risk patients with aggressive lymphoma according to the age-adjusted international prognostic index. [3] [4] [5] Otherwise, ASCT can also be considered as an attractive treatment option for mantle-cell lymphoma (MCL) patients under 60 years. 6, 7 Since the 1980's, various conditioning regimens have been used and none of them has demonstrated superiority to another. To date, BEAM (carmustine 300 mg/m 2 IV on day − 6, etoposide 100 mg/m 2 IV bid on day − 5 to − 2, cytarabine 100 mg/m 2 IV bid on day − 5 to − 2, melphalan 140 mg/m 2 on day − 1)-conditioning regimen is one of the standards of care for first line or relapsed NHL patients receiving consolidation with ASCT. 8, 9 Carmustine, one of the components of BEAM, is currently unavailable in France, due to a lack of production. In this situation, we had to make an institutional decision about an alternative conditioning regimen to use in lymphoid neoplasms such as NHL.
At the same time, promising data have been reported concerning safety and efficacy of bendamustine associated with EAM. The Be-EAM (bendamustine 200 mg/m 2 IV on day − 7 and − 6 in place of carmustine) regimen was found to be safe and effective for heavily pretreated lymphoma patients. 10 We began to use this Be-EAM since January 2014 in our center. Hematological toxicity seemed to be globally the same as described by Visani et al. Nevertheless we noticed uncommon non-hematological complications, in particular creatinine elevation early after the beginning of chemotherapy. Thus, we aimed to examine in more detail safety of this new conditioning.
We analyzed 29 consecutive patients diagnosed with DLBCL and MCL who received ASCT in first CR conditioned with Be-EAM between January 2014 and November 2014. We compared them with a cohort of 58 patients treated with the standard BEAM between January 2011 and December 2013. Patient characteristics are listed in Table 1 . All of them benefited of a pre-transplant assessment including transfer lung factor for carbon monoxide, left ventricular ejection fraction measured by echocardiogram, liver enzymes, blood urea nitrogen and creatinine blood tests.
The features of engraftment, hematological toxicities, infectious and non-hematological complications of the two cohorts are summarized in Table 2 . Strikingly, we observed a higher incidence of nephrotoxicity in the Be-EAM patients. Indeed, nine (31%) patients developed early renal toxicity before the day of reinfusion including four (14%) patients with a grade 3-4 renal impairment. At day +30 after reinfusion, cumulative incidence of nephrotoxicity was 48% (17% of grade 3-4), whereas in the BEAM cohort, renal impairment only concerned 7% of patients (5% of grade 3-4, P o0.001) and no patient developed creatinine elevation before reinfusion. Admission to the intensive care unit was necessary for seven (24%) patients versus 10% in the BEAM group (P = 0.07) because of septic shock and six of them experienced grade 2-4 renal toxicity associated with febrile neutropenia. Grade 2-3 cardiac toxicity was also observed in 10% of patients (versus 2% in the BEAM cohort, P = 0.02) and consisted in reversible atrial fibrillation (two patients) and atrial flutter (one patient) always associated with sepsis.
None of these patients had history of renal impairment and creatinine level was normal for all patients on pre-transplant assessment. We systematically performed a renal ultrasound when creatinine increased and no patient had urinary obstruction. Three patients had urinary tests showing no proteinuria, hematuria nor leukocyturia. Urinary ionogram displayed NA/K ratio o 1 and urinary urea o 100 consistent with tubular impairment. Among the patients who developed early renal toxicity, three were currently treated with antihypertensive drugs modifying intrarenal hemodynamics (hydrochlorothiazide and inhibitors of reninangiotensin system). Five patients who developed nephrotoxicity associated with sepsis received also antibiotics inducing tubular toxicities (aminoglycosides and glycopeptides). None of them was treated with CYP1A2 inducers but two patients were injected an iodine-containing contrast medium before a computed tomography scan. Full renal function recovery could be observed for all patients within 3 weeks but one who presented a septic shock requiring transitory dialysis. Taking together, these data argue for multifactorial acute tubular necrosis even through no renal biopsy was performed to confirm it. Renal injury was not associated with sex, age, body mass index and platinum-based induction therapy. Bendamustine mechanism of action associates alkylating activity of the mustard drugs and antimetabolite activity of the purine analogs. Bendamustine was widely used in relapsed/ refractory patients with CLL and indolent NHL, and demonstrated efficacy as first-line treatment for patients with indolent and mantle-cell lymphoma. 11 Thus, bendamustine is effective in resistant patients who do not respond to alkylating agents.
Little is known about feasibility and toxicity of bendamustine as ASCT-conditioning regimens. A previous report prospectively evaluated the clinical features of 42 patients with resistant/ relapsed NHL or Hodgkin disease enrolled in a phase I-II study. Be-EAM regimen appeared to be effective and safe in heavily pretreated patients and provided a 72% 3-year PFS. 10, 12 In the phase I trial, Visani et al. used increasing doses of bendamustine (160 mg/m 2 , 180 mg/m 2 and 200 mg/m 2 at day − 7 and − 6) and did not report any cardiac or renal toxicity. Bendamustine-based conditioning for patients with CLL before allogeneic stem cell transplantation did not show grade 3-4 cardiac or renal toxicity at the maximum dose of 130 mg/m 2 during 3 consecutive days. 13 In another phase I study of patients with myeloma treated with intensive chemotherapy, authors limited the dose escalation of bendamustine at 225 mg/m 2 total dose and observed 8% of atrial fibrillation, 4% of sinus tachycardia and 4% of pre-renal acute kidney injury.
14 This dose was chosen due to a prior report of cardiac toxicity in patients receiving bendamustine at a dose of 280 mg/m 2 once every 3 weeks as a single agent to treat solid tumors. 15 Our results have shown an increasing risk of renal toxicity with a current dose of 400 mg/m 2 total dose. Consequently, we decided in our institution to use an intermediate dose of 160 mg/m 2 per day for 2 consecutive days and to enhance hydration before the beginning of conditioning. Renal pretransplant assessment is precisely performed and renal function is strictly monitored. Therapies modifying intra-renal hemodynamics or increasing tubular toxicity are used carefully in particular during conditioning chemotherapy or in case of sepsis. Furthermore, Be-EAM conditioning is not recommended for patients with significant co-morbidities (severe hypertension (HTA), chronic renal or cardiac failure).
In conclusion, Be-EAM is feasible for patients with poor prognosis DLBCL and MCL but is associated with an increasing risk of renal and cardiac toxicity in comparison with the standard BEAM.
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